{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T18:51:43Z","timestamp":1789757503205,"version":"4.0.1"},"reference-count":121,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,2,21]],"date-time":"2018-02-21T00:00:00Z","timestamp":1519171200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2018.00027","type":"journal-article","created":{"date-parts":[[2018,2,21]],"date-time":"2018-02-21T11:35:37Z","timestamp":1519212937000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":79,"title":["The Expression and Prognostic Impact of Immune Cytolytic Activity-Related Markers in Human Malignancies: A Comprehensive Meta-analysis"],"prefix":"10.3389","volume":"8","author":[{"given":"Constantinos","family":"Roufas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Chasiotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anestis","family":"Makris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christodoulos","family":"Efstathiades","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apostolos","family":"Zaravinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,2,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3389\/fonc.2016.00233","article-title":"Combination approaches with immune-checkpoint blockade in cancer therapy","volume":"6","author":"Swart","year":"2016","journal-title":"Front Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1084\/jem.173.5.1099","article-title":"Cytotoxic T lymphocyte granules are secretory lysosomes, containing both perforin and granzymes","volume":"173","author":"Peters","year":"1991","journal-title":"J Exp Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/nri911","article-title":"Functional significance of the perforin\/granzyme cell death pathway","volume":"2","author":"Trapani","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/0092-8674(93)90326-L","article-title":"Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family","volume":"75","author":"Suda","year":"1993","journal-title":"Cell"},{"key":"B7","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1038\/nrc2465","article-title":"The TRAIL apoptotic pathway in cancer onset, progression and therapy","volume":"8","author":"Johnstone","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/nm.3394","article-title":"Microenvironmental regulation of tumor progression and metastasis","volume":"19","author":"Quail","year":"2013","journal-title":"Nat Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/nrc2618","article-title":"Microenvironmental regulation of metastasis","volume":"9","author":"Joyce","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3125","DOI":"10.1158\/0008-5472.CAN-11-4094","article-title":"Cellular constituents of immune escape within the tumor microenvironment","volume":"72","author":"Kerkar","year":"2012","journal-title":"Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.immuni.2013.10.003","article-title":"Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer","volume":"39","author":"Bindea","year":"2013","journal-title":"Immunity"},{"key":"B12","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s00262-011-1172-6","article-title":"An immune-active tumor microenvironment favors clinical response to ipilimumab","volume":"61","author":"Ji","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1056\/NEJMc1508163","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"373","author":"Chan","year":"2015","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s10555-015-9594-9","article-title":"Neutrophils: important contributors to tumor progression and metastasis","volume":"34","author":"Swierczak","year":"2015","journal-title":"Cancer Metastasis Rev"},{"key":"B16","doi-asserted-by":"publisher","first-page":"6058147","DOI":"10.1155\/2016\/6058147","article-title":"Tumor-associated macrophages and neutrophils in tumor microenvironment","volume":"2016","author":"Kim","year":"2016","journal-title":"Mediators Inflamm"},{"key":"B17","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1189\/jlb.5MR1216-508R","article-title":"Neutrophils as active regulators of the immune system in the tumor microenvironment","volume":"102","author":"Shaul","year":"2017","journal-title":"J Leukoc Biol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"60","DOI":"10.12788\/j.sder.0081","article-title":"Current status and future directions of molecularly targeted therapies and immunotherapies for melanoma","volume":"33","author":"Miller","year":"2014","journal-title":"Semin Cutan Med Surg"},{"key":"B19","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1097\/PPO.0b013e3181c51f0d","article-title":"Novel immunotherapies","volume":"15","author":"Yi","year":"2009","journal-title":"Cancer J"},{"key":"B20","doi-asserted-by":"publisher","first-page":"12472","DOI":"10.18632\/oncotarget.2998","article-title":"Classification of current anticancer immunotherapies","volume":"5","author":"Galluzzi","year":"2014","journal-title":"Oncotarget"},{"key":"B21","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/imr.12132","article-title":"Exploiting the curative potential of adoptive T-cell therapy for cancer","volume":"257","author":"Hinrichs","year":"2014","journal-title":"Immunol Rev"},{"key":"B22","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"E1151","DOI":"10.3390\/ijms17071151","article-title":"A mini-review for cancer immunotherapy: molecular understanding of PD-1\/ PD-L1 pathway & translational blockade of immune checkpoints","volume":"17","author":"Li","year":"2016","journal-title":"Int J Mol Sci"},{"key":"B24","doi-asserted-by":"publisher","first-page":"rv4","DOI":"10.1126\/scitranslmed.aad7118","article-title":"PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations","volume":"8","author":"Zou","year":"2016","journal-title":"Sci Transl Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1101\/gr.165985.113","article-title":"Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival","volume":"24","author":"Brown","year":"2014","journal-title":"Genome Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"4951","DOI":"10.1158\/1078-0432.CCR-13-0551","article-title":"Tumor-infiltrating lymphocytes in glioblastoma are associated with specific genomic alterations and related to transcriptional class","volume":"19","author":"Caleb Rutledge","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"eaal3321","DOI":"10.1126\/science.aal3321","article-title":"A subcellular map of the human proteome","volume":"356","author":"Thul","year":"2017","journal-title":"Science"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1260419","DOI":"10.1126\/science.1260419","article-title":"Proteomics. Tissue-based map of the human proteome","volume":"347","author":"Uhl\u00e9n","year":"2015","journal-title":"Science"},{"key":"B29","doi-asserted-by":"publisher","first-page":"eaan2507","DOI":"10.1126\/science.aan2507","article-title":"A pathology atlas of the human cancer transcriptome","volume":"357","author":"Uhlen","year":"2017","journal-title":"Science"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1074\/mcp.M500279-MCP200","article-title":"A human protein atlas for normal and cancer tissues based on antibody proteomics","volume":"4","author":"Uhlen","year":"2005","journal-title":"Mol Cell Proteomics"},{"key":"B31","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","article-title":"Molecular and genetic properties of tumors associated with local immune cytolytic activity","volume":"160","author":"Rooney","year":"2015","journal-title":"Cell"},{"key":"B32","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1038\/cdd.2016.12","article-title":"SynTarget: an online tool to test the synergetic effect of genes on survival outcome in cancer","volume":"23","author":"Amelio","year":"2016","journal-title":"Cell Death Differ"},{"key":"B33","volume-title":"Williams Hematology","author":"Kaushansky","year":"2010"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1073\/pnas.0538056100","article-title":"Single-cell perforin and granzyme expression reveals the anatomical localization of effector CD8+ T cells in influenza virus-infected mice","volume":"100","author":"Johnson","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1056\/NEJMoa051424","article-title":"Effector memory T cells, early metastasis, and survival in colorectal cancer","volume":"353","author":"Pag\u00e8s","year":"2005","journal-title":"N Engl J Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"5944","DOI":"10.1200\/JCO.2008.19.6147","article-title":"In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer","volume":"27","author":"Pag\u00e8s","year":"2009","journal-title":"J Clin Oncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"18538","DOI":"10.1073\/pnas.0509182102","article-title":"Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+\/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer","volume":"102","author":"Sato","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B38","first-page":"3932","article-title":"Prognostic significance of activated CD8+ T cell infiltrations within esophageal carcinomas","volume":"61","author":"Schumacher","year":"2001","journal-title":"Cancer Res"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1002\/cncr.23712","article-title":"Predominant infiltration of macrophages and CD8+ T cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer","volume":"113","author":"Kawai","year":"2008","journal-title":"Cancer"},{"key":"B40","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/PAP.0000000000000161","article-title":"Assessing tumor-infiltrating lymphocytes in solid tumors","volume":"24","author":"Hendry","year":"2017","journal-title":"Adv Anat Pathol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1158\/1078-0432.CCR-16-2128","article-title":"Immune cytolytic activity stratifies molecular subsets of human pancreatic cancer","volume":"23","author":"Balli","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B42","doi-asserted-by":"publisher","first-page":"200ra116","DOI":"10.1126\/scitranslmed.3006504","article-title":"Up-regulation of PD-L1, IDO, and Tregs in the melanoma tumor microenvironment is driven by CD8+ T cells","volume":"5","author":"Spranger","year":"2013","journal-title":"Sci Transl Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes (TILS) in breast cancer: recommendations by an International TILS Working Group 2014","volume":"26","author":"Salgado","year":"2015","journal-title":"Ann Oncol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"7155","DOI":"10.4049\/jimmunol.0803107","article-title":"Human milk-derived B cells: a highly activated switched memory cell population primed to secrete antibodies","volume":"182","author":"Tuaillon","year":"2009","journal-title":"J Immunol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1172\/JCI67428","article-title":"CD4+ follicular helper T cell infiltration predicts breast cancer survival","volume":"123","author":"Gu-Trantien","year":"2013","journal-title":"J Clin Invest"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1016\/j.humpath.2011.12.013","article-title":"Tumor-infiltrating lymphocytes are important pathologic predictors for neoadjuvant chemotherapy in patients with breast cancer","volume":"43","author":"Yamaguchi","year":"2012","journal-title":"Hum Pathol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1200\/JCO.2011.41.0902","article-title":"Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98","volume":"31","author":"Loi","year":"2013","journal-title":"J Clin Oncol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1093\/annonc\/mdu191","article-title":"Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients","volume":"25","author":"Ali","year":"2014","journal-title":"Ann Oncol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00262-017-2061-4","article-title":"Tumor infiltrating lymphocytes in lymph node metastases of stage III melanoma correspond to response and survival in nine patients treated with ipilimumab at the time of stage IV disease","volume":"67","author":"Diem","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"B50","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/nature04444","article-title":"Restoring function in exhausted CD8 T cells during chronic viral infection","volume":"439","author":"Barber","year":"2006","journal-title":"Nature"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1182\/blood-2008-12-195792","article-title":"Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired","volume":"114","author":"Ahmadzadeh","year":"2009","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","first-page":"5240","DOI":"10.4049\/jimmunol.0803245","article-title":"PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients","volume":"182","author":"Fourcade","year":"2009","journal-title":"J Immunol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1182\/blood-2008-09-179697","article-title":"Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression","volume":"114","author":"Mumprecht","year":"2009","journal-title":"Blood"},{"key":"B54","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat Med"},{"key":"B55","first-page":"6501","article-title":"B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma","volume":"63","author":"Strome","year":"2003","journal-title":"Cancer Res"},{"key":"B56","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1073\/pnas.0611533104","article-title":"Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer","volume":"104","author":"Hamanishi","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B57","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1158\/1078-0432.CCR-04-1469","article-title":"Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer","volume":"11","author":"Ohigashi","year":"2005","journal-title":"Clin Cancer Res"},{"key":"B58","doi-asserted-by":"publisher","first-page":"e65821","DOI":"10.1371\/journal.pone.0065821","article-title":"PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer","volume":"8","author":"Song","year":"2013","journal-title":"PLoS One"},{"key":"B59","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.critrevonc.2016.02.001","article-title":"PD-L1 expression in cancer patients receiving anti PD-1\/PD-L1 antibodies: a systematic review and meta-analysis","volume":"100","author":"Gandini","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"5023","DOI":"10.2147\/OTT.S105862","article-title":"PD-L1 expression in human cancers and its association with clinical outcomes","volume":"9","author":"Wang","year":"2016","journal-title":"Onco Targets Ther"},{"key":"B61","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.febslet.2013.10.015","article-title":"Checkpoint blocking antibodies in cancer immunotherapy","volume":"588","author":"Kyi","year":"2014","journal-title":"FEBS Lett"},{"key":"B62","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12916-016-0623-5","article-title":"Cancer immunotherapy: the beginning of the end of cancer?","volume":"14","author":"Farkona","year":"2016","journal-title":"BMC Med"},{"key":"B63","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00608-2","article-title":"Predictors of responses to immune checkpoint blockade in advanced melanoma","volume":"8","author":"Jacquelot","year":"2017","journal-title":"Nat Commun"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1093\/carcin\/bgv123","article-title":"Immunosuppression associated with chronic inflammation in the tumor microenvironment","volume":"36","author":"Wang","year":"2015","journal-title":"Carcinogenesis"},{"key":"B66","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1097\/CJI.0b013e318156e47e","article-title":"Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis","volume":"30","author":"Yang","year":"2007","journal-title":"J Immunother"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1200\/JCO.2008.19.2435","article-title":"Phase I\/II trial of tremelimumab in patients with metastatic melanoma","volume":"27","author":"Camacho","year":"2009","journal-title":"J Clin Oncol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.uct.2007.09.001","article-title":"Anti-CTLA4 antibody clinical trials in melanoma","volume":"2","author":"Ribas","year":"2007","journal-title":"Update Cancer Ther"},{"key":"B69","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1200\/JCO.2012.44.6112","article-title":"Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma","volume":"31","author":"Ribas","year":"2013","journal-title":"J Clin Oncol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1634\/theoncologist.12-7-873","article-title":"Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer","volume":"12","author":"Ribas","year":"2007","journal-title":"Oncologist"},{"key":"B71","first-page":"11","article-title":"Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma","volume":"10","author":"Berman","year":"2010","journal-title":"Cancer Immun"},{"key":"B72","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s40425-017-0218-5","article-title":"Combination immunotherapy: a road map","volume":"5","author":"Ott","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B73","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/j.1600-065X.2008.00608.x","article-title":"Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives","volume":"222","author":"Rodr\u00edguez","year":"2008","journal-title":"Immunol Rev"},{"key":"B74","doi-asserted-by":"publisher","first-page":"5498","DOI":"10.1158\/0008-5472.CAN-08-2106","article-title":"Efficacy of levo-1-methyl tryptophan and dextro-1-methyl tryptophan in reversing indoleamine-2,3-dioxygenase-mediated arrest of T-cell proliferation in human epithelial ovarian cancer","volume":"69","author":"Qian","year":"2009","journal-title":"Cancer Res"},{"key":"B75","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1080\/1475636021000006252","article-title":"Arginase activity is inhibited by L-NAME, both in vitro and in vivo","volume":"17","author":"Reisser","year":"2002","journal-title":"J Enzyme Inhib Med Chem"},{"key":"B76","doi-asserted-by":"publisher","first-page":"e1295903","DOI":"10.1080\/2162402X.2017.1295903","article-title":"Preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma","volume":"6","author":"Garg","year":"2017","journal-title":"Oncoimmunology"},{"key":"B77","doi-asserted-by":"publisher","first-page":"2","DOI":"10.4172\/2155-9899.1000322","article-title":"Cancer neoantigens: a promising source of immunogens for cancer immunotherapy","volume":"6","author":"Shigehisa Kitano","year":"2015","journal-title":"J Clin Cell Immunol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"B79","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1093\/intimm\/dxw019","article-title":"The role of neoantigens in response to immune checkpoint blockade","volume":"28","author":"Riaz","year":"2016","journal-title":"Int Immunol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"key":"B81","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1126\/science.1251102","article-title":"Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer","volume":"344","author":"Tran","year":"2014","journal-title":"Science"},{"key":"B82","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/nature14426","article-title":"Mutant MHC class II epitopes drive therapeutic immune responses to cancer","volume":"520","author":"Kreiter","year":"2015","journal-title":"Nature"},{"key":"B83","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1126\/science.aaa3828","article-title":"A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells","volume":"348","author":"Carreno","year":"2015","journal-title":"Science"},{"key":"B84","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nature13988","article-title":"Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens","volume":"515","author":"Gubin","year":"2014","journal-title":"Nature"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1158\/0008-5472.CAN-11-3722","article-title":"Exploiting the mutanome for tumor vaccination","volume":"72","author":"Castle","year":"2012","journal-title":"Cancer Res"},{"key":"B86","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nature18945","article-title":"Neoantigen landscape dynamics during human melanoma-T cell interactions","volume":"536","author":"Verdegaal","year":"2016","journal-title":"Nature"},{"key":"B87","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1158\/1078-0432.CCR-16-2569","article-title":"Immunotherapy for breast cancer: what are we missing?","volume":"23","author":"Vonderheide","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B88","doi-asserted-by":"publisher","first-page":"3585","DOI":"10.7150\/thno.21471","article-title":"Genomic analysis of tumor microenvironment immune types across 14 solid cancer types: immunotherapeutic implications","volume":"7","author":"Chen","year":"2017","journal-title":"Theranostics"},{"key":"B89","doi-asserted-by":"publisher","first-page":"934.e","DOI":"10.1016\/j.cell.2017.09.028","article-title":"Tumor and microenvironment evolution during immunotherapy with nivolumab","volume":"171","author":"Riaz","year":"2017","journal-title":"Cell"},{"key":"B90","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N Engl J Med"},{"key":"B91","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/nature07205","article-title":"Cancer-related inflammation","volume":"454","author":"Mantovani","year":"2008","journal-title":"Nature"},{"key":"B92","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.1007\/s10875-012-9847-0","article-title":"Cancer-related inflammation","volume":"33","author":"Candido","year":"2013","journal-title":"J Clin Immunol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nature01322","article-title":"Inflammation and cancer","volume":"420","author":"Coussens","year":"2002","journal-title":"Nature"},{"key":"B94","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","article-title":"Immunity, inflammation, and cancer","volume":"140","author":"Grivennikov","year":"2010","journal-title":"Cell"},{"key":"B95","doi-asserted-by":"publisher","first-page":"e1069938","DOI":"10.1080\/2162402X.2015.1069938","article-title":"Immunological metagene signatures derived from immunogenic cancer cell death associate with improved survival of patients with lung, breast or ovarian malignancies: a large-scale meta-analysis","volume":"5","author":"Garg","year":"2016","journal-title":"Oncoimmunology"},{"key":"B96","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/bjc.1974.233","article-title":"Lymphoreticular infiltration in human tumours: prognostic and biological implications: a review","volume":"30","author":"Underwood","year":"1974","journal-title":"Br J Cancer"},{"key":"B97","first-page":"13","article-title":"T-lymphocyte subsets in primary lung cancer","volume":"17","author":"Tsuyuguchi","year":"1987","journal-title":"Jpn J Clin Oncol"},{"key":"B98","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/nrclinonc.2015.215","article-title":"Clinical relevance of host immunity in breast cancer: from TILs to the clinic","volume":"13","author":"Savas","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"B100","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1158\/2159-8290.CD-15-1545","article-title":"Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade","volume":"6","author":"Chen","year":"2016","journal-title":"Cancer Discov"},{"key":"B101","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1126\/science.aaa6204","article-title":"T cell exclusion, immune privilege, and the tumor microenvironment","volume":"348","author":"Joyce","year":"2015","journal-title":"Science"},{"key":"B102","first-page":"1405","article-title":"Hepatocyte growth factor production by neutrophils infiltrating bronchioloalveolar subtype pulmonary adenocarcinoma: role in tumor progression and death","volume":"63","author":"Wislez","year":"2003","journal-title":"Cancer Res"},{"key":"B103","doi-asserted-by":"publisher","first-page":"4709","DOI":"10.1200\/JCO.2008.18.9498","article-title":"Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma","volume":"27","author":"Jensen","year":"2009","journal-title":"J Clin Oncol"},{"key":"B104","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1002\/ijc.25892","article-title":"Polymorphonuclear granulocytes in human head and neck cancer: enhanced inflammatory activity, modulation by cancer cells and expansion in advanced disease","volume":"129","author":"Trellakis","year":"2011","journal-title":"Int J Cancer"},{"key":"B105","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.semcancer.2013.02.001","article-title":"Immunomonitoring and prognostic relevance of neutrophils in clinical trials","volume":"23","author":"Donskov","year":"2013","journal-title":"Semin Cancer Biol"},{"key":"B106","doi-asserted-by":"publisher","first-page":"e98259","DOI":"10.1371\/journal.pone.0098259","article-title":"Tumor-associated neutrophils as a new prognostic factor in cancer: a systematic review and meta-analysis","volume":"9","author":"Shen","year":"2014","journal-title":"PLoS One"},{"key":"B107","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13058-015-0558-3","article-title":"Granulocytic immune infiltrates are essential for the efficient formation of breast cancer liver metastases","volume":"17","author":"Tabari\u00e8s","year":"2015","journal-title":"Breast Cancer Res"},{"key":"B108","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nature16140","article-title":"Neutrophils support lung colonization of metastasis-initiating breast cancer cells","volume":"528","author":"Wculek","year":"2015","journal-title":"Nature"},{"key":"B109","doi-asserted-by":"publisher","first-page":"12493","DOI":"10.1073\/pnas.0601807103","article-title":"Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis","volume":"103","author":"Nozawa","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B110","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.semcancer.2013.02.003","article-title":"Neutrophil-mediated tumour angiogenesis: subversion of immune responses to promote tumour growth","volume":"23","author":"Tazzyman","year":"2013","journal-title":"Semin Cancer Biol"},{"key":"B111","first-page":"175","article-title":"The role of neutrophils as cytotoxic cells in lung metastasis: suppression of tumor cell metastasis by a biological response modifier (PSK)","volume":"12","author":"Ishihara","year":"1998","journal-title":"In Vivo"},{"key":"B112","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.ccr.2011.08.012","article-title":"Tumor entrained neutrophils inhibit seeding in the premetastatic lung","volume":"20","author":"Granot","year":"2011","journal-title":"Cancer Cell"},{"key":"B113","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1038\/onc.2012.201","article-title":"Neutrophil chemokines secreted by tumor cells mount a lung antimetastatic response during renal cell carcinoma progression","volume":"32","author":"L\u00f3pez-Lago","year":"2013","journal-title":"Oncogene"},{"key":"B114","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/nature14407","article-title":"MET is required for the recruitment of anti-tumoural neutrophils","volume":"522","author":"Finisguerra","year":"2015","journal-title":"Nature"},{"key":"B115","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/cdd.2017.15","article-title":"Pathogen response-like recruitment and activation of neutrophils by sterile immunogenic dying cells drives neutrophil-mediated residual cell killing","volume":"24","author":"Garg","year":"2017","journal-title":"Cell Death Differ"},{"key":"B116","doi-asserted-by":"publisher","first-page":"701067","DOI":"10.1155\/2015\/701067","article-title":"Distinct functions of neutrophil in cancer and its regulation","volume":"2015","author":"Granot","year":"2015","journal-title":"Mediators Inflamm"},{"key":"B117","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s12307-014-0147-5","article-title":"The multifaceted roles neutrophils play in the tumor microenvironment","volume":"8","author":"Sionov","year":"2015","journal-title":"Cancer Microenviron"},{"key":"B118","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nrc.2016.52","article-title":"Neutrophils in cancer: neutral no more","volume":"16","author":"Coffelt","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"B119","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/imr.12444","article-title":"Neutrophils in cancer","volume":"273","author":"Treffers","year":"2016","journal-title":"Immunol Rev"},{"key":"B120","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1158\/2326-6066.CIR-15-0313","article-title":"The complex role of neutrophils in tumor angiogenesis and metastasis","volume":"4","author":"Liang","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B121","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1007\/s00262-013-1476-9","article-title":"Tumor-associated neutrophils (TAN) develop pro-tumorigenic properties during tumor progression","volume":"62","author":"Mishalian","year":"2013","journal-title":"Cancer Immunol Immunother"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fonc.2018.00027\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,2,21]],"date-time":"2018-02-21T11:35:39Z","timestamp":1519212939000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fonc.2018.00027\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,21]]},"references-count":121,"alternative-id":["10.3389\/fonc.2018.00027"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2018.00027","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,21]]},"article-number":"27"}}